1. Activation of MAPKs influences the expression of drug-metabolizing enzymes in primary human hepatocytes.
- Author
-
Bachleda P, Vrzal R, and Dvorák Z
- Subjects
- Anisomycin pharmacology, Aryl Hydrocarbon Hydroxylases metabolism, Dioxins pharmacology, Enzyme Activation drug effects, Enzyme Activators pharmacology, Epidermal Growth Factor metabolism, Glucuronosyltransferase metabolism, Glutathione Transferase metabolism, Hepatocytes drug effects, Hepatocytes metabolism, Humans, Phenobarbital pharmacology, RNA, Messenger metabolism, Rifampin pharmacology, Sorbitol pharmacology, Sulfotransferases metabolism, Extracellular Signal-Regulated MAP Kinases metabolism, Hepatocytes enzymology
- Abstract
We examined the effects of model activators of mitogen-activated protein kinases (MAPKs) on basal and rifampicin-, phenobarbital- and dioxin-inducible expression of phase I and phase II biotransformation enzymes in primary human hepatocytes. Cells were treated for 24 h with sorbitol (SOR), anisomycin (ANI) and epidermal growth factor (EGF) in the presence or absence of inducers. The levels of CYP1A1, CYP1A2, CYP2B6, CYP3A4, UGT1A1, UGT2B17, SULT1A1, SULT2A1, SULT1B2, GSTA1, GSTA2 mRNAs were determined. SOR and EGF inhibited the expression of the tested genes, while ANI had no effect. We conclude that MAPKs play important role in the transcriptional regulation of drug-metabolizing enzymes.
- Published
- 2009